Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Domestic single-dose flu drug approved

By WANG XIAOYU | CHINA DAILY | Updated: 2025-07-19 08:45
Share
Share - WeChat

China's top drug regulator announced on Friday that it has approved a domestically developed flu drug requiring only a single dose throughout the entire treatment course, offering a new solution for an illness that infects five to 10 percent of adults globally each year.

The first-in-class innovative drug has been authorized to treat adult patients with uncomplicated influenza A and B, excluding those at high risk of severe flu-related complications, according to a statement from the National Medical Products Administration.

The drug, named ZX-7101A in clinical trials, was developed by Zenshine, a pharmaceutical company in Nanjing, Jiangsu province.

Results from a late-stage clinical trial, led by research teams at the National Medical Center for Infectious Diseases at Fudan University's Huashan Hospital in Shanghai, were published in the international journal Clinical Microbiology and Infection in January. The study found that ZX-7101A effectively treated influenza with a single dose of either 40 milligrams or 80 mg and caused no major adverse reaction.

Participants who received a single dose experienced quicker symptom relief and tested negative for the virus faster than those given a placebo. Fever symptoms also subsided significantly within less than 24 hours, according to the study.

In a statement released on Friday, the company said the drug also demonstrated a low incidence of adverse reactions, with gastrointestinal side effects occurring in only 0.3 percent.

"This significantly reduces the clinical challenge of frequent nausea, vomiting, and diarrhea associated with traditional anti-influenza drugs," the statement said.

Additionally, the drug's unique metabolic mechanism lowers the risk of drug-drug interactions, meaning it won't interfere with other medications taken simultaneously.

"It provides a safer therapeutic option for patients with multiple conditions requiring medications," the company said.

Yang Jinfu, cofounder and chairman of the company, said that they will accelerate research into the drug's potential for treating other age groups and work to expand its approved age range.

The first and most widely used single-dose antiviral flu pill is baloxavir marboxil, marketed as Xofluza and developed by the global pharmaceutical giant Roche. It was first approved in China in April 2021.

With this latest approval, China now has two domestically developed medications that could potentially rival Roche's product.

The other domestic single-dose flu treatment, suraxavir marboxil, was developed by a Jiangxi-based drugmaker and approved by the National Medical Products Administration in March.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 美女解开胸罩摸自己胸直播| 99久久99这里只有免费费精品 | 大伊香蕉在线精品不卡视频| 国产丰满乱子伦无码专区| 久久91精品国产99久久yfo| 欧美精品一二三| 啊灬用力啊灬啊灬快灬深| fc2成年免费共享视频网站| 欧美成视频无需播放器| 国产成人一区二区三区高清| 99这里只精品热在线获取| 无敌小保子笔趣阁| 亚洲av第一网站久章草| 爱妺妺国产av网站| 国产91伦子系列沙发午睡| 色综合a怡红院怡红院首页| 在线观看欧洲成人免费视频| 亚洲国产欧美另类va在线观看| 精品综合久久久久久888蜜芽| 国产欧美一区二区精品久久久| a级国产乱理伦片| 抽搐一进一出在深一点| 亚洲av中文无码乱人伦在线视色| 烈血黄昏中视频| 同桌一直在夹腿还嗯啊的叫| 黑人狠狠的挺身进入| 国产高清无专砖区2021| 一本久久a久久精品亚洲| 日本免费精品一区二区三区| 亚洲乱人伦中文字幕无码| 波多野结衣种子网盘| 午夜不卡久久精品无码免费| 香蕉视频久久久| 国产精品亚洲视频| 99热精品久久只有精品30 | 国产欧美日韩在线观看一区二区 | 国产一区二区三区免费在线观看| 亚洲成a人片在线不卡| 国产麻豆一级在线观看| h片在线免费观看| 性欧美暴力猛交xxxxx高清|